UBS Assumes Bristol-Myers Squibb at Neutral, Lowers Price Target of $60
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Trung Huynh has assumed Bristol-Myers Squibb (NYSE:BMY) with a Neutral rating and has lowered the price target to $60.
October 20, 2023 | 11:57 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS analyst has given Bristol-Myers Squibb a Neutral rating and lowered the price target to $60.
The news directly pertains to Bristol-Myers Squibb as UBS analyst has given a Neutral rating and lowered the price target. This could potentially impact the stock's performance in the short term as it might influence investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100